Plau Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Plau Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The PLAU gene (Plasminogen Activator, Urokinase) encodes urokinase-type plasminogen activator, a serine protease that converts plasminogen to plasmin. PLAU has roles in extracellular proteolysis, cell migration, and is implicated in neurodegeneration.
| Attribute | Value |
|---|---|
| Gene Symbol | PLAU |
| Full Name | Plasminogen Activator, Urokinase |
| Chromosomal Location | 10q22.2 |
| NCBI Gene ID | 5328 |
| OMIM | 191340 |
| Ensembl ID | ENSG00000122861 |
| UniProt ID | P00750 |
Urokinase (uPA) is a key fibrinolytic enzyme:
PLAU initiates a proteolytic cascade:
| Receptor | Function |
|---|---|
| uPAR | Cell surface receptor for uPA |
| LRP1 | Clearance receptor |
| Integrins | Cell adhesion/migration |
| VN | Vitronectin binding |
Beyond proteolysis, uPA activates:
PLAU is expressed in multiple cell types:
| Cell Type | Expression Level | Function |
|---|---|---|
| Neurons | High | Synaptic plasticity |
| Astrocytes | Moderate | Migration |
| Microglia | High | Immune surveillance |
| Endothelial cells | High | Angiogenesis |
Expression is upregulated in response to injury and during neurodegenerative processes.
PLAU-targeted therapies:
Challenges:
Key findings from model systems:
Current research focus areas:
Plau Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Plau Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liot G, et al. uPA and uPAR in neurodegeneration and neuroregeneration. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1240-1246. PMID:18460451
Belec L, et al. Urokinase-type plasminogen activator in neurological diseases. J Neurol Sci. 2001;187(1-2):69-76. PMID:11250432
Siao CJ, et al. Urokinase-type plasminogen activator is a therapeutic target in neurodegeneration. J Exp Med. 2003;198(7):1079-1085. PMID:14517273
Jeon H, et al. uPA deficiency leads to impaired synaptic plasticity. Mol Neurobiol. 2019;56(12):8202-8214. PMID:31175589
Zhao J, et al. Plasminogen activator and neurodegeneration. Neurosci Bull. 2015;31(3):389-396. PMID:25900488